Replacement of the P1 Amino Acid of Human Immunodeficiency Virus Type 1 Gag Processing Sites Can Inhibit or Enhance the Rate of Cleavage by the Viral Protease by Pettit, S. C. et al.
JOURNAL OF VIROLOGY, Oct. 2002, p. 10226–10233 Vol. 76, No. 20
0022-538X/02/$04.000 DOI: 10.1128/JVI.76.20.10226–10233.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Replacement of the P1 Amino Acid of Human Immunodeficiency
Virus Type 1 Gag Processing Sites Can Inhibit or Enhance the
Rate of Cleavage by the Viral Protease
Steve C. Pettit,1† Gavin J. Henderson,1,2 Celia A. Schiffer,3 and Ronald Swanstrom1*
UNC Center for AIDS Research1 and Department of Microbiology and Immunology,2 University of North Carolina at
Chapel Hill, Chapel Hill, North Carolina 27599-7295, and Department of Pharmacology and Molecular
Toxicology, University of Massachusetts Medical School, Worcester, Massachusetts 016553
Received 7 January 2002/Accepted 28 June 2002
Processing of the human immunodeficiency virus type 1 (HIV-1) Gag precursor is highly regulated, with
differential rates of cleavage at the five major processing sites to give characteristic processing intermediates.
We examined the role of the P1 amino acid in determining the rate of cleavage at each of these five sites by
using libraries of mutants generated by site-directed mutagenesis. Between 12 and 17 substitution mutants
were tested at each P1 position in Gag, using recombinant HIV-1 protease (PR) in an in vitro processing
reaction of radiolabeled Gag substrate. There were three sites in Gag (MA/CA, CA/p2, NC/p1) where one or
more substitutions mediated enhanced rates of cleavage, with an enhancement greater than 60-fold in the case
of NC/p1. For the other two sites (p2/NC, p1/p6), the wild-type amino acid conferred optimal cleavage. The
order of the relative rates of cleavage with the P1 amino acids Tyr, Met, and Leu suggests that processing sites
can be placed into two groups and that the two groups are defined by the size of the P1 amino acid. These
results point to a trans effect between the P1 and P1 amino acids that is likely to be a major determinant of
the rate of cleavage at the individual sites and therefore also a determinant of the ordered cleavage of the Gag
precursor.
Assembly of virus particles is highly regulated to ensure the
formation of a complex structure able to leave the cell, bind to
and enter a new cell, and initiate a new round of infection.
Most retroviruses use a strategy of assembly in which the viral
Gag precursor oligomerizes at the plasma membrane of the
cell and buds from the cell. The Gag and Gag-Pro-Pol polypro-
tein precursors that make up the bulk of the virion proteins
within the virus envelope are cleaved during virion maturation
by the viral protease, which is encoded in the pro gene and
initially embedded in the Gag-Pro-Pol precursor (50). The
timing of the initiation of these cleavages is regulated such that
the cleavage products remain in the virus particle, even though
processing appears to initiate while these polyprotein precur-
sors are still cell associated (20, 21, 23, 31).
The human immunodeficiency virus type 1 (HIV-1) Gag
precursor is cleaved at least five times to generate a series of
mature protein products (16, 17). There is an absolute require-
ment for cleavage at each of these sites, since substitutions at
the cleavage site that block processing invariably lead to the
production of aberrant and noninfectious virus particles (36,
58). Cleavage of the Gag precursor at these multiple sites also
appears to be highly regulated. Peptide substrates of these
different sites are cleaved by the viral protease at different
rates, and cleavage of the intact Gag precursor in vitro goes
through a distinct series of intermediates that are generated
due to different rates of cleavage at the various sites (4, 7, 9, 24,
30, 36, 38, 43, 52). The pattern of intermediates seen in in-
fected cells and in recently budded virus particles is consistent
with the ordered cleavage of Gag that has been observed in
vitro (11, 12, 29, 36, 56, 58). In the in vitro studies the initial
site of cleavage occurs at the site that defines the p2/NC
boundary to generate N-terminal and C-terminal intermedi-
ates of Gag (9, 24, 36). These intermediates are cleaved at an
approximately 10-fold-lower rate, at the MA/CA site in the
N-terminal intermediate and at the p1/p6 site in the C-terminal
intermediate (36). Finally, C-terminal spacer peptides are
trimmed from both the CA and NC proteins at the CA/p2 site
and the NC/p1 site in cleavage reactions that are up to several
hundred-fold slower than the initial cleavage (36). While the
order of these cleavages can be reproduced with peptide and
Gag substrates in vitro and a similar order can be inferred in
vivo, the absolute rates of cleavage from each of these systems
can vary or is not known.
Investigation of the characteristics of the sequences at pro-
tease cleavage sites has been an area of interest for under-
standing the nature of protease-substrate interaction and the
regulation of Gag processing and as a starting point for the
design of inhibitors of the HIV-1 protease. The amino acids
flanking the target scissile bond are generally hydrophobic (16,
33, 37). A number of studies have used peptide or Gag sub-
strates in an attempt to define the role of specific amino acids
at different positions flanking the scissile bond as they impact
the rate of cleavage by the viral protease (3, 5, 13, 14, 19, 30, 34,
36, 38, 44, 45, 51, 53–55; recently reviewed in reference 27). In
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the present study we have examined the ability of approxi-
mately 15 different amino acids in the P1 position of the five
different Gag cleavage sites to support cleavage by the HIV-1
protease (the P1 position is the amino acid immediately up-
stream of the scissile bond, and the P1 position is the amino
acid immediately downstream of the scissile bond). We used
full-length Gag as a substrate for cleavage with recombinant
protease. This system allowed us to examine the relative rates
of cleavage under conditions that were more physiological than
those typically used to detect the cleavage of peptides (which
include the use of low pH and high salt concentrations). We
confirmed the requirement for a hydrophobic amino acid at
the P1 position and found that certain of the substituted amino
acids are able to accelerate the rate of cleavage at certain sites,
indicating that the presence of suboptimal amino acids is re-
sponsible for some of the differences observed in the rates of
processing of the various Gag sites. In addition, we were able
to classify processing sites into two groups, defined by the size
of the amino acid in the P1 position, which varied in the order
of cleavage efficiency of Met, Leu, and Tyr to function as a P1
amino acid.
MATERIALS AND METHODS
Plasmid construction and mutagenesis, and transfection. The phagemid
pGagS was described previously (36) and contains the 5 noncoding region and
gag gene from HIV-1 molecular clone HXB (accession no. NC001802) (42), with
the inserted sequences placed between the XbaI and SalI sites of pIBI20 (US
Biochemicals). HXB sequences extend from the NarI site at base 182 to the BclI
site at base 1974.
The infectious molecular clone, pCadN, is a recombinant between the HXB
infectious clone (42) and the NL4-3 infectious clone (1) (accession no. M19921).
To create pCadN, a translationally silent unique XbaI site was created in the MA
domain of both clones by a single T-to-C transition (HXB base 683; NL4-3 base
1029) using site-directed mutagenesis (2, 25, 36). In pCadN, HXB sequences
replaced NL4-3 sequences from the unique XbaI site to the EcoRV site in pol
(HXB base 2522; NL4-3 base 2977). The remainder of the viral sequences are
derived from NL4-3.
Site-directed mutagenesis, and in vitro transcription and translation. Mu-
tagenesis of the codon encoding the P1 amino acid of the five major Gag
processing sites in pGagS was performed as previously described using uracil-
substituted single-stranded templates (2, 25, 36). Individual oligonucleotides 30
nucleotides in length and degenerate for the P1 codon were used during site-
directed mutagenesis to generate a library of random substitution mutations for
each site. Mutations were identified by DNA sequencing with modified T7 DNA
polymerase (U.S. Biotechnologies).
pGagS, linearized with SalI, was used in in vitro transcription with T7 RNA
polymerase (Promega) to produce capped mRNA transcripts of gag as described
previously (36). Translation of the synthetic mRNA in a rabbit reticulocyte lysate
(Promega) to generate radiolabeled Gag protein was performed as described
previously (36) with 50-l reaction mixtures containing 50 Ci of [35S]cysteine
(1,000 Ci/mM) (DuPont NEN). The completed translations were either used
immediately or stored briefly at 20°C prior to use.
In vitro assay for the proteolytic processing of Gag. The Gag precursor was
processed in 50-l reaction mixtures containing 5 l of the Gag-containing rabbit
reticulocyte lysate and 0.2 to 5 g of purified recombinant protease in phosphate-
buffered saline at pH 7.0 (0.8% [wt/vol] NaCl, 0.02% KCl, 0.012% KH2PO4,
0.091% Na2HPO4). Purified protease was prepared as described previously (36).
The amount of added protease was adjusted for the particular site examined so
that nearly complete cleavage of the wild-type sequence at that site occurred
roughly 1 h into the time course of the reaction. Reactions were performed for
6 h at 30°C. At various times, 5-l aliquots were removed and the reaction was
stopped by the addition of an equal volume of sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis (SDS-PAGE) loading buffer (26). Products of the
processing reaction were heated to 100°C prior to separation by electrophoresis
in a 17% polyacrylamide gel with a Tris-glycine buffer (46). After electrophoresis,
gels were fixed in 10% acetic acid and dried followed by autoradiography and
phosphorimaging.
Densitometic analysis of Gag processing reactions and calculation of the
relative rates of cleavage. Relative quantitation of Gag precursor and products
was performed by densitometric analysis using a Molecular Dynamics 840 Storm
PhosphorImager. The relative rates of cleavage between P1-mutated Gag sub-
strates for a particular site were estimated as described previously (36, 49). The
estimate of the relative amount of each protein species was first corrected for the
number of cysteine residues available to label in that species. The amount of
uncleaved substrate for a particular mutation was determined as the total sum of
precursors and intermediates containing the uncleaved site; reduced processing
at some sites resulted in the appearance of new intermediates, whose identities
were inferred based on size (36). In some instances the amounts of some inter-
mediates could not be determined because of unincorporated radioactivity in the
range of 7 to 10 kDa present in gels or because of secondary cleavage at minor
sites within the precursor. In these cases, the indiscernible intermediates were
not included in the calculation of the total uncleaved substrate. In all cases, total
inhibition of cleavage at a site was judged by the absence of the final processed
product. The calculations of the relative rates of cleavage were performed as
described previously (36) from semilog (first-order) plots. The slope of the line
derived from points in the midcourse of cleavage (20 to 80% cleavage) was used
as a numerical value of relative rate.
Construction of infectious HIV-1 DNA clones, transfection, and Western blot
analysis of released virions. DNA fragments containing mutations at the NC/p1
site were removed from pGagS by digestion with ApaI and BclI and used to
replace the same fragment in pCadN. A 20-g aliquot of purified pCadN was
transfected into an 80% confluent monolayer of HeLa cells in a 100-mm-diam-
eter plate by the CaCl2 procedure described by Chen and Okayama (6). At 48 h
posttransfection, the medium was collected and clarified by low-speed centrifu-
gation (5,000  g for 10 min). The relative amount of released virus in the
medium was determined using a reverse transcriptase assay (32). Similar
amounts of virus (from approximately 10 ml of medium) were pelleted by
centrifugation at 100,000  g for 90 min. After removal of the supernatant, the
pellet was resuspended in 100 l of SDS-PAGE buffer and heated to 100°C prior
to Western blot analysis.
A 10-l portion of the resuspended virion protein solution was electropho-
resed in a 12% polyacrylamide–Tris–tricine gel (46) and then subjected to west-
ern blot analysis (36). After transfer to a polyvinylidene difluoride membrane
(Schleicher & Schuell), blots were blocked with 1% bovine serum albumin in
Tris-buffered saline–0.1% Tween 20 and then exposed to a 1:1,000 dilution of
anti-nucleocapsid polyclonal primary antibody from rabbit in phosphate-buffered
saline (48, 49). The colormetric signal was developed as described previously (35,
36).
RESULTS
There are five major cleavage sites in the HIV-1 Gag pre-
cursor (Fig. 1A). Cleavage of the Gag precursor in vitro with
the viral protease gives rise to a series of distinct intermediates
(Fig. 1B). These intermediates arise because the various cleav-
age sites are cleaved at roughly three distinct rates (Fig. 1C),
with the initial cleavage occurring at the p2/NC site to generate
a 41-kDa intermediate (MA-CA-p2) and the p15 intermediate
(NC-p1-p6). Cleavage of these two intermediates follows, at
the MA/CA site and the p1/p6 site and at a rate approximately
10-fold lower than the initial cleavage. Finally, the two C-
terminal spacer peptides, at the CA/p2 boundary and the
NC/p1 boundary, are cleaved at a rate approximately 400-fold
slower than the initial cleavage at the p2/NC site. We explored
the potential role of the P1 amino acid (i.e., the amino acid
immediately upstream of the scissile bond and generating the
C-terminal carboxylate after cleavage of the peptide bond) in
regulating the rate of cleavage at these sites. The position of
the codon encoding the P1 amino acid was randomly mu-
tagenized in the gag expression vector pGagS (36), and indi-
vidual clones were screened by sequence analysis to identify a
majority of the possible substitution mutations at each site.
Between 12 and 17 of the 19 possible substitution mutants at
each of the P1 positions at the five major cleavage sites were
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identified. In this system it is possible to determine if a substi-
tution enhances the rate of cleavage, and the sensitivity for
detecting reduced rates of cleavage extends to the range of a
20- to 30-fold reduction in rate relative to the wild-type site.
Cleavage that occurs at a rate lower than 20- to 30-fold that of
the wild-type site would not be detected and is reported as not
cleaved.
gag mRNA was generated from each of the mutagenized
plasmids in the pGagS backbone by using an in vitro transcrip-
tion system. The mRNA was translated in vitro in the presence
of [35S]cysteine to generate a radiolabeled Gag substrate. The
translation product was incubated for various periods with
recombinant HIV-1 protease, and the cleavage products were
resolved by PAGE under reducing and denaturing conditions.
The relative rate of cleavage at each of the major Gag cleavage
sites was monitored as a function of time, and the different
cleavage products were quantified by PhosphorImager analy-
sis. The relative rate of cleavage at each mutated site was
determined from the percentage of the total precursors and
intermediates containing the uncleaved site under study, as
described in the Materials and Methods.
Mutagenesis of the P1 position of the p2/NC cleavage site.
Each of 16 P1 substitution mutants was analyzed in parallel
reactions for the relative rate of cleavage at the p2/NC site
(ATIM/MQR). These results are shown in Fig. 2 and summa-
FIG. 1. Processing of the HIV-1 Gag precursor in vitro. (A) Schematic representation of the Pr55 Gag precursor with the five major processing
sites shown as vertical lines. The sequence of the individual sites from the P4 through P3 is shown above. The rates of cleavage of the five sites
relative to the initially cleaved p2/NC site is shown below, as determined by cleavage in vitro with recombinant protease (36). (B) Representative
SDS-PAGE gel showing ordered processing in vitro of the wild-type Gag precursor as a function of time in the presence of recombinant HIV-1
protease. The positions of the Gag precursor, processing intermediates, and mature products are shown on the left. The positions of molecular
mass markers are shown on the right. (C) Plot of the time course of cleavage of the five processing sites as derived from densitometric analysis
of gels of the processing reaction. The plot is derived from the summation of the percent initially uncleaved substrate containing each individual
processing site over time.
FIG. 2. Effect of substitutions of the P1 amino acid on the cleavage
of the p2/NC site in vitro. The plot shows the percentage of initially
uncleaved p2/NC site (as precursor and intermediates) over the time
course of the assay. Only substitutions that allowed some degree of
cleavage are shown in the plot.
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rized in Table 1. The mutants fall into five categories with
respect to their effect on cleavage at the p2/NC site: Phe was
cleaved at a rate equivalent to the wild type (Met); Leu was
cleaved at a rate estimated to be approximately three times
lower; Cys, Trp, and Tyr were cleaved approximately 10 times
slower than the wild type; and Ala was cleaved 22 times slower
than the wild type. The remaining amino acids did not support
any detectable cleavage (with the exception of His, Lys, and
Asn, which were not tested).
Mutagenesis of the P1 position of the MA/CA cleavage site.
A total of 17 substitution mutations of the wild-type Tyr were
tested at the P1 position of the MA/CA cleavage site (SQNY/
PIV; Asn and Trp were not tested). Only four amino acids
other than the wild type supported cleavage (Fig. 3; Table 1).
A Phe substitution accelerated cleavage at this site nearly
2-fold, while Met, Leu, and Cys substitutions were cleaved
between 4- and 14-fold slower.
Mutagenesis of the P1 position of the p1/p6 cleavage site.
Only one of the 14 substitutions tested to replace the wild-type
Phe supported cleavage at this site (PGNF/LQS); a Met sub-
stitution supported cleavage at a rate approximately sixfold
lower than the wild type (Table 1). The other 13 amino acid
substitutions tested did not support measurable cleavage (Gln,
Arg, Thr, Val, and Tyr were not tested).
Mutagenesis of the P1 position of the CA/p2 cleavage site.
Of the 14 amino acid substitutions tested 2 supported cleavage
of the CA/p2 site (ARVL/AEA) faster than the wild-type Leu,
with both Phe and Tyr showing accelerated cleavage at approx-
imately a twofold higher rate (Table 1). Cys was the only other
substitution that supported cleavage but at a rate threefold
lower than the wild type (Glu, Lys, Met, Gln, and Arg, were
not tested). Using peptide substrates, Ridky et al. (45) re-
ported an increase in the rate of cleavage with a Phe but a
slight decrease with a P1 Tyr at this site.
Mutagenesis of the P1 position of the NC/p1 cleavage site. A
total of 12 substitutions were tested in place of the wild-type
Asn at the P1 position of the NC/p1 cleavage site (RQAN/
FLG; Asp, Glu, His, Pro, Arg, Thr, and Trp were not tested).
Surprisingly, only 3 amino acid substitutions failed to permit
cleavage, while 9 of the 12 substitutions tested gave detectable
cleavage. Furthermore, the wild-type Asn supported cleavage
poorly relative to five of the substitution mutants, with Phe and
Met accelerating cleavage by at least 60-fold (Table 1) and
Leu, Tyr, and Cys all accelerating cleavage 30- to 3-fold. Fi-
nally, even amino acids with beta-branched side chains (Val
and Ile) were able to support a low level of cleavage (Table 1).
Examples of the patterns of Gag cleavage are shown in Fig. 4A
for a subset of NC/p1 mutants, with examples of a Gly substi-
tution blocking cleavage, a Phe substitution accelerating cleav-
age, and a Val substitution slowing cleavage. Note that these
different rates of NC/p1 processing were seen while the rates of
cleavage of other sites in Gag were similar (e.g., compare
CA/p2 cleavage). The wide range and rates of cleavage of the
substitution mutants with mutations at the NC/p1 cleavage site
contrasts with the restricted range of allowed substitutions at
CA/p2, even though these two sites have similar rates of cleav-
age for the wild-type sequences.
More complete cleavage of mutant NC/p1 cleavage sites in
the virus. We examined the potential of selected mutants of
the NC/p1 cleavage site to alter the extent of cleavage of the
NC/p1 intermediate in the assembled virus. HeLa cells were
transfected with a full-length HIV-1 genome or with a version
of this genome encoding an NC/p1 cleavage site with a substi-
tution at the P1 position. The Gly, Ser, Phe, and Tyr substitu-
tion mutants were tested in this system as examples of substi-
tutions that mediated cleavage over a wide range of rates.
Supernatant virus that was produced after the transfection was
FIG. 3. Effect of substitutions of the P1 amino acid on the cleavage
of the MA/CA site in vitro. The plot shows the amount of initially
uncleaved MA/CA processing site over the time course of the assay.
Only substitutions that allowed some degree of cleavage are shown in
the plot.
TABLE 1. Activity of P1 substitution mutants for cleavage by the HIV-1 protease
Cleavage site
(wild-type P1)
Relative activity of P1 amino acid mutanta:
A C D E F G H I K L M N P Q R S T V W Y
MA/CA (Y) ()b 0.05 () () 1.5 () () () () 0.1 0.25 NDc () () () () () () ND 1
CA/p2 (L) () 0.35 () ND 2 () () () ND 1 ND () () ND ND () () () () 2
p2/NC (M) 0.0 0.15 () () 1 () ND () ND 0.35 1 ND () () () () () () 0.1 0.1
NC/p1 (N) 0.5 3 ND ND 60 0.05 ND 0.1 () 30 60 1 ND () ND () ND 0.15 ND 20
p1/p6 (F) () () () () 1 () () () () () 0.15 () () ND ND () ND ND () ND
a Rates are estimated from the slope of the line describing the rate of loss of the processing intermediates with that site relative to the rate of cleavage of the wild-type
site.
b (), not cleaved at a rate at least 3 to 5% of the wild-type rate.
c ND, not done (this mutation was not recovered in the library of random P1 mutations).
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collected, concentrated by centrifugation, and analyzed by
SDS-PAGE followed by Western analysis with an antibody
specific for NC. In this system the wild-type virions displayed
the expected processing products (including mature NC) as
well as several processing intermediates including the p15
(NC-p1-p6) and NC-p1 intermediates (Fig. 4B). The Ser sub-
stitution blocked the processing of NC/p1 since no mature NC
protein was present in virus particles; similarly, this Ser sub-
stitution blocked cleavage at this site in vitro (Table 1). Gly,
which supported only a low level of processing in vitro (Fig.
4A), blocked the processing of NC/p1 as seen by the absence of
mature NC in virus particles (Fig. 4B). In contrast, both Phe
and Tyr, each of which accelerated the rate of processing in
vitro (Table 1, Fig. 4A), supported more extensive cleavage of
NC/p1 in vivo compared to the wild type (Fig. 4B). Thus, for
this site the in vitro results were consistent with the effect on
processing as inferred from the protein composition of virus
particles.
In an initial analysis of the effect of these mutations on virus
infectivity, we have placed several of these mutations into a
full-length infectious clone. Using a single-cycle infectivity as-
say, we found that the Tyr and Phe substitutions were compat-
ible with a high level of infectivity while the Ser substitution
supported only a very low level of infectivity (data not shown).
Thus, while limiting cleavage at this site severly affected infec-
tivity, mutations that strongly accelerated the rate of cleavage
in vitro were not significantly deleterious to infectivity.
DISCUSSION
In these studies we have characterized the role of the P1
amino acid in determining the rate of cleavage by the HIV-1
protease at the five predominant processing sites in the HIV-1
Gag precursor. Approximately 15 different amino acids were
tested at each of these sites for their ability to support cleavage
by the viral protease. These analyses were carried out using
full-length Gag precursor as substrate with more physiological
reaction conditions of neutral pH and low salt concentration
rather than the conditions of low pH and high salt concentra-
tion that are typically used in the analysis of cleavage of pep-
tide substrates. Our results confirmed previous observations
that the P1 position prefers a hydrophobic and non-beta-
branched amino acid. In addition, we were able to add suffi-
cient quantitation to these studies to be able to draw several
unexpected conclusions.
One surprising outcome of these studies is the observation
that for three of the five sites the rate of cleavage could be
FIG. 5. Summary of the activity of Gag P1 processing site muta-
tions. The values presented in Table 1 were corrected for the rate of
cleavage of the individual sites relative to each other, as described in
the legend to Fig. 1 and reference 36. After correcting for the relative
rates, all rates were multiplied by 100 so that the rate of the first site
cleaved (p2/NC) has a value of 100. For each site, the rate of cleavage
of the wild-type sequence is shown by the black bar. The individual
sites and the substitutions that supported detectable cleavage are
shown at the bottom of the graph. The asterisks indicate that the actual
rate was greater than the rate shown but by an unknown amount.
FIG. 4. Cleavage of the NC/p1 site in vitro and in vivo. (A) Time courses of cleavage in vitro of the wild type (WT) and P1 mutants with
mutations of the NC/p1 site. Gag processing intermediates (including NC-p1) are shown on the left, as well as the mature products (including NC).
The P1 substitution mutant is noted above the relevant gel. (B) Extent of processing of NC-containing Gag products in released virus with P1
substitutions at the NC/p1 site. Virion-associated precursors, intermediates, and products containing NC were detected with a specific antibody
reagent in a Western analysis as described in Material and Methods. The compositions of NC-containing precursors and products are shown on
the left, and the positions of molecular mass markers are shown on the right. The P1 substitution mutation of the NC/p1 cleavage site is shown
at the top of the relevant lane.
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improved with the introduction of specific alternative amino
acids at the P1 position (summarized in Fig. 5). Only the
p2/NC site and the p1/p6 site could not be improved. This
observation provides clear evidence that the rate of cleavage at
these sites, and perhaps their order of cleavage, is regulated by
the use of suboptimal amino acids in the cleavage sites. Using
peptide substrates, Ridky et al. (45) observed a 42% increase in
the rate of cleavage at the CA/p2 site with a P1 Phe in place of
the wild-type Leu, although they observed a decrease in the
rate of cleavage with a P1 Tyr at this site. Tritch et al. (55)
observed an increase in the rate of cleavage of the MA/CA site
with a P1 Phe in place of Tyr, similar to our observation (Fig.
3), and Partin et al. (34) observed that Phe readily substituted
for Tyr at this site. Both increased and decreased rates of
cleavage for a P1 Phe have been reported for equivalent pep-
tide substrates of the MA/CA site (3, 54).
There are constraints that may dictate the use of some sub-
optimal amino acids. The P1 Pro in the MA/CA site is re-
quired to participate in a specific interaction that is unique to
the processed form of CA and an integral part of virion mat-
uration (10, 57). Pro is the P1 amino acid in several processing
sites, although this distinctive requirement for Pro after cleav-
age is known only for CA, and this is a conserved feature of the
upstream cleavage site of CA among retroviruses (37, 57). It
may be that the requirement for Pro in this postcleavage in-
teraction provides the selective pressure to be able to accom-
modate Pro in the P1 site of the protease target sequence,
defining a maximum rate of cleavage even with an optimal P1
amino acid. The P1 amino acid Asn of the NC/p1 site contrib-
utes its third codon position U to the slippery sequence that
directs the 1 frameshifting event that allows expression of the
Gag-Pro-Pol precursor (18, 59). The potential importance of
this P1 amino acid (or its underlying coding sequence) can be
seen in the fact that a compensatory mutation to increase the
rate of cleavage at this site in the presence of a protease
inhibitor-resistant protease occurs through a change in the P2
position (Ala to Val) (8, 28, 61). Introduction into a virus (with
a wild-type protease) of the P2 position Val at the NC/p1 site
has a small negative effect on infectivity (8, 28). However, the
NC/p1 site does not appear to be overly sensitive to up regu-
lation since a Phe or Tyr substitution at the P1 site retains
significant infectivity (data not shown).
The other surprising conclusion derived from these experi-
ments is that the processing sites appear to fall into two groups,
based on the pattern of activity associated with a specific subset
of P1 amino acids: Phe, Met, Tyr, and Leu. In group 1 sites
(p2/NC and NC/p1), the aliphatic amino acids Met and Leu
confer activity that is more similar to Phe, while Tyr is the least
active of this group of amino acids. In contrast, the group 2
sites (MA/CA and CA/p2) display activity with Tyr similar to
that with Phe, while Met and Leu show lesser activity. For the
p1/p6 site, Met is significantly less active than Phe, with Leu
being inactive; Tyr was not tested at this site, but overall the
site appears to follow the group 2 pattern (Fig. 5).
An examination of the amino acids flanking the P1 position
in the cleavage sites suggests an explanation for the existence
of these two groups of sites. In group 1 sites (P1 Phe/Met/Leu),
the P1 amino acid is large, either Phe or Met. In the group 2
sites (P1 Phe/Tyr), the P1 amino acid is smaller (Pro, Ala, and
Leu). Given that the substrate cleavage site assumes a beta-
sheet-like conformation in the active site of the protease (60),
this linkage suggests a significant trans interaction between the
P1 and P1 amino acids flanking the scissile bond. The trans
interaction between P1 and P1 appears to provide a better
explanation of the data than the trans interaction between P1
and P2 or the cis interactions between P1 and P3 or P1 and P2.
In some HIV-1 isolates, the P1 Leu is replaced with Pro in the
p1/p6 site, maintaining an amino acid in the small group
(group 2). In contrast, increases in the rate of processing of the
p1/p6 site in the presence of a protease inhibitor-resistant
protease are effected by a P1 change of Leu to Phe (8, 61),
introducing a P1 amino acid from the large group (group 1).
The issue of cis and trans interactions has been addressed
with the HIV-1 protease by Ridky et al. (44), who examined
the effects of single and double substitutions in peptide sub-
strates representing the Rous sarcoma virus NC/PR cleavage
site (PAVS/LAM). They noted that a P1 Trp or a P1 Leu
improved the activity of a substrate with a P1 Ala beyond what
was expected and suggested that the large P1 amino acid po-
sitioned the small Ala side chain deeper in the S1 subsite. We
considered a similar structural model to explain the observed
trans effect inferred from our studies. However, in comparing
the crystal structures of the protease with six peptide substrates
(representing the cleavage sites at MA/CA, CA/p2, p2/NC,
p1/p6, RT/RH, and RH/IN) (40, 41), we found no evidence for
the physical displacement of either the P1 or the P1 amino
acid side chain due to a trans effect. As an alternative model,
we have considered the possibility that the sizes of the P1 and
P1 amino acids are somehow additive and can be too large for
optimal cleavage. Thus, a P1 Tyr would be most active with
small P1 amino acids and less active with Tyr or Phe in the P1
position. We previously observed that aliphatic amino acids at
the P1 position of the MA/CA cleavage site (with a P1 Tyr)
were more active than Phe or Tyr (22), although other studies
using similar peptide substrates have not observed this rank
order (3, 54). Ridky et al. (45) reported that aliphatic amino
acids and Phe, when used instead of the P1 Ala in the CA/p2
site, enhanced the rate of cleavage. In the substrate-PR crystal
structures, Tyr makes a significant number of contacts in either
the P1 or P1 position, and it is also able, through its side chain
hydroxyl, to make additional contacts with solvent, perhaps
enhancing its binding energy. The additive effects of the P1 and
P1 amino acids in defining the rate of cleavage and in passing
through an optimum are consistent with the data obtained in
this study (Table 1).
Hydrophobic beta-branched amino acids are never found in
naturally occurring protease cleavage sites (37, 39), and a
structural reason for their exclusion has been proposed (54). In
contrast, a site with a P1 Ile substitution of the RSV NC/PR is
cleaved by the Rous sarcoma virus protease (47). We have now
observed a low level of cleavage by the HIV-1 protease at the
NC/p1 site with either Val or Ile at the P1 position (Table 1;
Fig. 5). We did not see cleavage at the CA/p2 site with either
Val or Ile, even though the rates of cleavage at the NC/p1 and
CA/p2 wild-type sequences are similar. This difference may be
due to the large P1 amino acid in the NC/p1 site contributing
to an enhanced rate of cleavage with suboptimal P1 amino
acids. Thus, we confirm that the protease can cleave a peptide
bond with a beta-branched P1 amino acid, although in our case
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we did not analyze the position of the cleaved site by protein
sequencing.
In summary, our results point to significant trans interactions
between the P1 and P1 side chains of HIV-1 protease sub-
strates in determining the rate of cleavage. Phe appears best
suited to productively interacting with the S1 subsite and per-
haps the S1 subsite. Met and Leu are more active when an
amino acid with a larger P1 side chain occupies the S1 sub-
site, and Tyr is more active with amino acids with smaller P1
side chains occupying the S1 subsite. These results suggest a
basis for two groupings of the diverse cleavage site sequences
as an alternative to older classification schemes that had fo-
cused largely on the presence or absence of a P1 Pro (13, 15,
37).
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